Skip to main content
SpringerLink
Log in

Monoclonal Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

  • Chapter
  • First Online:
Book cover Allogeneic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1428 Accesses

Abstract

Monoclonal antibodies have revolutionized the treatment of hematologic malignancies. The monoclonal antibody rituximab plays an integral part in the upfront treatment of both aggressive and indolent CD20-expressing non-Hodgkin’s lymphoma (NHL). Although allogeneic hematopoietic stem cell transplantation (HSCT) can be a curative therapy for many hematologic malignancies, much improvement remains to be made to reduce rates of regimen related-transplant toxicity, disease relapse and graft versus host disease (GVHD). The role of monoclonal antibodies in allogeneic HSCT is still being investigated. We have reviewed recent evidence supporting the use of monoclonal antibodies in allogeneic transplantation and have given our recommendations as to the best way to incorporate them in the transplant process.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446

    Article  PubMed  CAS  Google Scholar 

  2. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M (2002) Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 119:923-929

    Article  PubMed  CAS  Google Scholar 

  3. Golay J, Zaffaroni L, Vaccari T et al (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908

    PubMed  CAS  Google Scholar 

  4. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683

    Article  PubMed  CAS  Google Scholar 

  5. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652

    PubMed  CAS  Google Scholar 

  6. Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992

    Article  PubMed  CAS  Google Scholar 

  7. Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008

    Article  PubMed  CAS  Google Scholar 

  8. van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301

    Article  PubMed  Google Scholar 

  9. Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127

    Article  PubMed  CAS  Google Scholar 

  10. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117-4126

    Article  PubMed  CAS  Google Scholar 

  11. Press OW, Appelbaum F, Ledbetter JA et al (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591

    PubMed  CAS  Google Scholar 

  12. Clift RA, Buckner CD, Appelbaum FR et al (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76:1867-1871

    PubMed  CAS  Google Scholar 

  13. Clift RA, Buckner CD, Appelbaum FR et al (1991) Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77:1660-1665

    PubMed  CAS  Google Scholar 

  14. Alvarnas JC, Forman SJ (2004) Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled. Oncology (Williston Park) 18:867-876 discussion 876-878, 881, 884

    Google Scholar 

  15. Jacobsen E, Freedman A (2004) B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol 5:711-717

    Article  PubMed  CAS  Google Scholar 

  16. Khouri IF, Lee MS, Saliba RM et al (2004) Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32:28-35

    Article  PubMed  CAS  Google Scholar 

  17. Press OW, Eary JF, Appelbaum FR et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224

    Article  PubMed  CAS  Google Scholar 

  18. Press OW, Eary JF, Appelbaum FR et al (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340

    Article  PubMed  CAS  Google Scholar 

  19. Press OW, Eary JF, Gooley T et al (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942

    PubMed  CAS  Google Scholar 

  20. Gopal AK, Gooley TA, Maloney DG et al (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102:2351-2357

    Article  PubMed  CAS  Google Scholar 

  21. Nademanee A, Forman S, Molina A et al (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896-2902

    Article  PubMed  CAS  Google Scholar 

  22. Shimoni A, Zwas ST, Oksman Y et al (2007) Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin’s lymphoma. Exp Hematol 35:534-540

    Article  PubMed  CAS  Google Scholar 

  23. Gopal AK, Rajendran JG, Gooley TA et al (2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396-1402

    Article  PubMed  Google Scholar 

  24. Fietz T, Uharek L, Gentilini C et al (2006) Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 47:59-63

    Article  PubMed  CAS  Google Scholar 

  25. Gopal AK, Rajendran JG, Pagel JM et al (2006) A phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL). Blood 108:316a

    Google Scholar 

  26. Matthews DC, Appelbaum FR, Eary JF et al (1995) Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-1131

    PubMed  CAS  Google Scholar 

  27. Matthews DC, Appelbaum FR, Eary JF et al (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94:1237-1247

    PubMed  CAS  Google Scholar 

  28. Pagel JM, Appelbaum FR, Eary JF et al (2006) 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107:2184-2191

    Article  PubMed  CAS  Google Scholar 

  29. Zenz T, Glatting G, Schlenk RF et al (2006) Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. Haematologica 91:285-286

    PubMed  Google Scholar 

  30. Bunjes D (2002) 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 43:2125-2131

    Article  PubMed  CAS  Google Scholar 

  31. Ringhoffer M, Blumstein N, Neumaier B et al (2005) 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 130:604-613

    Article  PubMed  CAS  Google Scholar 

  32. Burke JM, Caron PC, Papadopoulos EB et al (2003) Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 32:549-556

    Article  PubMed  CAS  Google Scholar 

  33. Gribben JG, Neuberg D, Freedman AS et al (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457

    PubMed  CAS  Google Scholar 

  34. Zwicky CS, Maddocks AB, Andersen N, Gribben JG (1996) Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin’s lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 88:3314-3322

    PubMed  CAS  Google Scholar 

  35. Horwitz SM, Negrin RS, Blume KG et al (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783

    Article  PubMed  CAS  Google Scholar 

  36. Brugger W, Hirsch J, Grunebach F et al (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15:1691-1698

    Article  PubMed  CAS  Google Scholar 

  37. Neumann F, Harmsen S, Martin S et al (2006) Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol 85:530-534

    Article  PubMed  CAS  Google Scholar 

  38. Mangel J, Leitch HA, Connors JM et al (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 15:283-290

    Article  PubMed  CAS  Google Scholar 

  39. Shimoni A, Hardan I, Avigdor A et al (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin’s lymphoma. Br J Haematol 122:457-464

    Article  PubMed  CAS  Google Scholar 

  40. Roman E, Cooney E, Harrison L et al (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 11:7164s-7170s

    Article  PubMed  CAS  Google Scholar 

  41. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139-170

    Article  PubMed  CAS  Google Scholar 

  42. Giralt S (2006) The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 33:S36-S43

    Article  PubMed  CAS  Google Scholar 

  43. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19:3685-3691

    PubMed  CAS  Google Scholar 

  44. Marmont AM, Horowitz MM, Gale RP et al (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130

    PubMed  CAS  Google Scholar 

  45. Wasil T, Rai KR, Mehrotra B (2004) The role of monoclonal antibodies in stem cell transplantation. Semin Oncol 31:83-89

    Article  PubMed  CAS  Google Scholar 

  46. Cull GM, Haynes AP, Byrne JL et al (2000) Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 108:754-760

    Article  PubMed  CAS  Google Scholar 

  47. Lush RJ, Haynes AP, Byrne J et al (2001) Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy 3:203-210

    Article  PubMed  CAS  Google Scholar 

  48. Novitzky N, Thomas V, Hale G, Waldmann H (2005) Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. Bone Marrow Transplant 36:675-682

    Article  PubMed  CAS  Google Scholar 

  49. Wagner JE, Thompson JS, Carter SL, Kernan NA (2005) Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366:733-741

    Article  PubMed  CAS  Google Scholar 

  50. D’Sa S, Peggs K, Pizzey A et al (2003) T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 123:309-322

    Article  PubMed  Google Scholar 

  51. Shore T, Harpel J, Schuster MW et al (2006) A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biol Blood Marrow Transplant 12:868-875

    Article  PubMed  CAS  Google Scholar 

  52. Perez-Simon JA, Kottaridis PD, Martino R et al (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121-3127

    Article  PubMed  CAS  Google Scholar 

  53. Novitzky N, Davison GM, Hale G, Waldmann H (2002) Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 74:1551-1559

    Article  PubMed  CAS  Google Scholar 

  54. Davison GM, Novitzky N, Kline A et al (2000) Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 69:1341-1347

    Article  PubMed  CAS  Google Scholar 

  55. Morris EC, Rebello P, Thomson KJ et al (2003) Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102:404-406

    Article  PubMed  CAS  Google Scholar 

  56. Dodero A, Carrabba M, Milani R et al (2005) Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 33:920-927

    Article  PubMed  CAS  Google Scholar 

  57. Chakrabarti S, MacDonald D, Hale G et al (2003) T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 121:109-118

    Article  PubMed  Google Scholar 

  58. Avivi I, Chakrabarti S, Milligan DW et al (2004) Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 10:186-194

    Article  PubMed  Google Scholar 

  59. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16-24

    Article  PubMed  CAS  Google Scholar 

  60. Chakrabarti S, Milligan DW, Pillay D et al (2003) Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 102:839-842

    Article  PubMed  CAS  Google Scholar 

  61. Avivi I, Chakrabarti S, Kottaridis P et al (2004) Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 34:137-142

    Article  PubMed  CAS  Google Scholar 

  62. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R (2006) Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath “in the bag” as T-cell depletion: the Leiden experience. Bone Marrow Transplant 37:1129-1134

    Article  PubMed  CAS  Google Scholar 

  63. Meyer RG, Britten CM, Wehler D et al (2007) Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 109:374-382

    Article  PubMed  CAS  Google Scholar 

  64. Khouri IF, Saliba RM, Admirand J et al (2007) Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137:355-363

    Article  PubMed  CAS  Google Scholar 

  65. Kebriaei P, Saliba RM, Ma C et al (2006) Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38:203-209

    Article  PubMed  CAS  Google Scholar 

  66. Escalon MP, Champlin RE, Saliba RM et al (2004) Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419-2423

    Article  PubMed  Google Scholar 

  67. Ho AY, Devereux S, Mufti GJ, Pagliuca A (2003) Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplant 31:551-557

    Article  PubMed  CAS  Google Scholar 

  68. Khouri IF, Lee MS, Saliba RM et al (2003) Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments.

This research was supported by NIH P01 Grant CA44991, SCOR grant #7040-05 from the Leukemia and Lymphoma Society, and gifts from David and Patricia Giuliani, Mary and Geary Britton-Simmons, and the Hext Family Foundation.

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA

    Maria Corinna Palanca-Wessels & Oliver Press

Authors
  1. Maria Corinna Palanca-Wessels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Press
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Palanca-Wessels, M.C., Press, O. (2010). Monoclonal Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_41

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation